For instance, a phase II trial involving 257 patients indicated that CD24-type alanine/valine single-nucleotide polymorphisms could predict pathological complete response (pCR) following neoadjuvant chemotherapy in primary breast cancer and modulate the host’s antitumor immune response. This evidence concerns the gene CD24 and breast carcinoma.